ALK-positive Non-Small Cell Lung Cancer Pipeline Summary

DelveInsight’s, “ALK-positive Non-Small Cell Lung Cancer - Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

ALK-positive Non-Small Cell Lung Cancer: Understanding

ALK-positive Non-Small Cell Lung Cancer: Overview

ALK-positive Non-Small Cell Lung Cancer (NSCLC) is a subtype of lung cancer characterized by a genetic alteration involving the anaplastic lymphoma kinase (ALK) gene. This alteration typically occurs due to a chromosomal rearrangement, leading to the fusion of the ALK gene with another gene, which causes uncontrolled cell growth and cancer development. ALK-positive NSCLC accounts for about 3-7% of all NSCLC cases, commonly affecting younger patients who are non-smokers or light smokers.The discovery of the ALK gene rearrangement in NSCLC has been pivotal in the shift toward personalized medicine in oncology. This subset of NSCLC is more common in adenocarcinoma, a type of NSCLC, and its identification has enabled the development of highly specific targeted therapies that directly inhibit the mutated ALK protein, offering more effective treatment options for patients.

ALK-positive non-small cell lung cancer (ALK+ NSCLC) is primarily caused by a chromosomal rearrangement involving the anaplastic lymphoma kinase (ALK) gene, most commonly the EML4-ALK fusion. This genetic alteration produces an abnormal ALK fusion protein with constitutive tyrosine kinase activity, leading to continuous activation of downstream signaling pathways that promote uncontrolled cell proliferation, survival, and tumor growth. ALK rearrangements occur in approximately 3–7% of NSCLC cases and are more frequently observed in younger patients, never- or light-smokers, and those with adenocarcinoma histology. Unlike smoking-related lung cancers, ALK+ NSCLC is driven predominantly by this oncogenic genetic alteration rather than environmental carcinogens.

ALK-positive Non-Small Cell Lung Cancer (NSCLC) is a subtype of lung cancer that is driven by a genetic mutation in the anaplastic lymphoma kinase (ALK) gene. Patients with ALK-positive NSCLC often present with symptoms that are common to other forms of lung cancer, such as persistent coughing, chest pain, shortness of breath, unexplained weight loss, and fatigue. As the disease progresses, symptoms may intensify, including coughing up blood, recurrent infections, or difficulty breathing.

Early and accurate diagnosis of ALK-positive NSCLC is critical for effective treatment. Testing for the ALK mutation involves molecular diagnostic techniques, including fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and next-generation sequencing (NGS). These tests are typically performed on biopsy samples of the tumor. Identifying ALK rearrangements helps oncologists tailor treatment specifically to target the mutated gene, enabling more personalized and effective therapy.

The treatment landscape for ALK-positive NSCLC has been transformed by targeted therapies. ALK inhibitors such as crizotinib, alectinib, and lorlatinib have demonstrated efficacy in halting disease progression and improving overall survival. These treatments work by specifically inhibiting the mutated ALK protein, which is driving the cancer's growth. Despite their effectiveness, patients may eventually develop resistance to these drugs, necessitating changes in treatment strategies. Additionally, radiation therapy, surgery, and chemotherapy may be considered depending on the stage of the cancer and the patient’s overall health. Immunotherapies, while less frequently used in ALK-positive cases, are another option in specific cases.

"ALK-positive Non-Small Cell Lung Cancer- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the ALK-positive Non-Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and ALK-positive Non-Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth ALK-positive Non-Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ALK-positive Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence ALK-positive Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve ALK-positive Non-Small Cell Lung Cancer.

ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Chapters

This segment of the ALK-positive Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

ALK-positive Non-Small Cell Lung Cancer Emerging Drugs

• TRI-611: TRIANA Biomedicines, Inc.

TRI-611 is a novel, orally available small-molecule therapeutic being developed for the treatment of KRAS-mutant non-small cell lung cancer (NSCLC). The drug is designed using TRIANA's targeted protein degradation platform to selectively bind to a previously inaccessible pocket on mutant KRAS, inducing its degradation rather than merely inhibiting its activity. By reducing intracellular KRAS protein levels, TRI-611 is intended to shut down aberrant RAS/MAPK signaling, a key driver of tumor growth and survival. This differentiated mechanism has the potential to provide broader and more durable antitumor activity, including in tumors that develop resistance to conventional KRAS inhibitors. Currently, the drug is in Phase I/II stage of its development for ALK-positive Non-Small Cell Lung Cancer (NSCLC).

Further product details are provided in the report……..

ALK-positive Non-Small Cell Lung Cancer: Therapeutic Assessment

This segment of the report provides insights about the different ALK-positive Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in ALK-positive Non-Small Cell Lung Cancer

There are approx. 5+ key companies which are developing the therapies ALK-positive Non-Small Cell Lung Cancer. The companies which have their ALK-positive Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Phase I/II include, TRIANA Biomedicines, Inc. and others.

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

ALK-positive Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

ALK-positive Non-Small Cell Lung Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ALK-positive Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ALK-positive Non-Small Cell Lung Cancer drugs.

ALK-positive Non-Small Cell Lung Cancer Report Insights

• ALK-positive Non-Small Cell Lung Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

ALK-positive Non-Small Cell Lung Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing ALK-positive Non-Small Cell Lung Cancer drugs?
• How many ALK-positive Non-Small Cell Lung Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ALK-positive Non-Small Cell Lung Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ALK-positive Non-Small Cell Lung Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for ALK-positive Non-Small Cell Lung Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• TRIANA Biomedicines, Inc.
• Shouyao Holdings (Beijing) Co. LTD

Key Products

• TRI-611
• SY-3505